Home Business News Pharma Giant Inches Higher As Cancer Drugs Drive Quarterly Beat

Pharma Giant Inches Higher As Cancer Drugs Drive Quarterly Beat

0
Pharma Giant Inches Higher As Cancer Drugs Drive Quarterly Beat

[ad_1]

Bristol Myers Squibb (BMY) topped third-quarter estimates on Wednesday as two cancer treatments helped drive growth, but BMY stock toppled to a 16-month low as Revlimid generics wait in the wings.




X



The company credited cancer drugs Revlimid and Opdivo, as well as blood thinner Eliquis for its strong growth. Revlimid and Eliquis tacked on double-digit growth. In response, the drug giant raised the low end of its full-year earnings outlook by a nickel.

Among its growth products, Bristol Myers noted double-digit declines for cancer treatments Abraxane and Empliciti. Abraxane was originally developed by biotech company Celgene before its Bristol Myers takeover in late 2019.

On today’s stock market today, BMY stock toppled 3% to 56.49. Shares are now well below their 50-day and 200-day moving averages, according to MarketSmith.com.

BMY Stock Falls Despite Beat

During the period ended Sept. 30, Bristol Myers earned $2 per share on $11.62 billion in sales. On a year-over-year basis, adjusted profit surged 23% and beat forecasts by 8 cents. Sales grew 10% and were just a hair above BMY stock analysts’ view for $11.61 billion.

Revlimid sales advanced 11% to $3.35 billion. Eliquis and Opdivo brought in $2.41 billion and $1.91 billion, respectively. Eliquis sales increased 15% and Opdivo sales rose 7%.

Revenue from new products Reblozyl and Inrebic soared a respective 67% and 69%, though the growth came from low bases. Reblozyl is a blood-disease treatment from Bristol and Acceleron Pharma (XLRN). The latter is being acquired by Bristol competitor Merck (MRK). Inrebic treats a bone marrow cancer called myelofibrosis.

See also  Sequoia to restructure itself away from traditional VC model

Another new treatment, Bluebird Bio (BLUE)-partnered Abecma generated $71 million. Abecma is a CAR-T drug that treats late-stage multiple myeloma, a blood cancer.

On the bearish side for BMY stock, Abraxane sales declined 22% and Empliciti sales fell 15% to a respective $266 million and $82 million.

Revlimid Competition Is Looming

Edward Jones analyst Ashtyn Evans called the quarter “solid” for Bristol Myers. She noted the substantial increases for Reblozyl and Abecma. But she reiterated her hold rating on BMY stock.

“Despite the strong results and continued progress in the company’s new drug pipeline, we continue to believe that sales growth for Bristol will be challenging once the patent protection for Revlimid expires next year,” she said in a report.

For the year, Bristol Myers expects worldwide sales to increase by a high-single digit percentage. BMY stock analysts called for $46.47 billion in sales, a 9.3% pop. The company also expects to earn $7.40-$7.55 per share vs. analysts’ forecast for $7.47 a share.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

The Eli Lilly-Biogen Clash In Alzheimer’s Begins — How Will It Play Out?

Pfizer, BioNTech Diverge As FDA Panel Mulls Covid Vaccine In Children

See Stocks On The List Of Leaders Near A Buy Point

Learn How To Time The Market With IBD’s ETF Market Strategy

Watch IBD’s Investing Strategies Show For Actionable Market Insights



[ad_2]

LEAVE A REPLY

Please enter your comment!
Please enter your name here